Transimmune is a pioneering dendritic cell therapy business that has discovered how dendritic cells are produced biologically.
Transimmune has raised $5.0M in total funding. The most recent round was Seed. The last funding was announced in September 2023.
Transimmune's investors include Bill & Melinda Gates Foundation.
Transimmune is headquartered in Düsseldorf, Germany.
Transimmune is a pioneering dendritic cell therapy business that has discovered how dendritic cells are produced biologically.
Transimmune is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Transimmune — Funding & Investors." VCBacked, September 20, 2023, https://www.vcbacked.co/company/transimmune. Accessed September 30, 2026.
VCBacked. (2023). Transimmune — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/transimmune
{{cite web |title=Transimmune — Funding & Investors |url=https://www.vcbacked.co/company/transimmune |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated